Read More

Bristol Myers Squibb’s Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients

Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with met

BMY